Cargando…

The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry

BACKGROUND: Immune checkpoint inhibitors (ICIs) are quickly becoming key instruments in the treatment of mismatch repair-deficient (dMMR) colorectal cancers (CRCs). Despite their clinical value, ICIs have several limitations associated with their use. Only approximately 15% of all CRCs have a dMMR s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Hongkai, Li, Yaqi, Wang, Xiaoyu, Qian, Juanjuan, Xu, Midie, Peng, Junjie, Huang, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163547/
https://www.ncbi.nlm.nih.gov/pubmed/35669431
http://dx.doi.org/10.3389/fonc.2022.867658
_version_ 1784719945553149952
author Yan, Hongkai
Li, Yaqi
Wang, Xiaoyu
Qian, Juanjuan
Xu, Midie
Peng, Junjie
Huang, Dan
author_facet Yan, Hongkai
Li, Yaqi
Wang, Xiaoyu
Qian, Juanjuan
Xu, Midie
Peng, Junjie
Huang, Dan
author_sort Yan, Hongkai
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors (ICIs) are quickly becoming key instruments in the treatment of mismatch repair-deficient (dMMR) colorectal cancers (CRCs). Despite their clinical value, ICIs have several limitations associated with their use. Only approximately 15% of all CRCs have a dMMR status, and the overall response rate of ICIs is approximately 40%. The mechanism of ICI resistance is not clear, and its study is limited by the lack of information available on the characterization of the immune microenvironment during the progression from early- to advanced-stage dMMR CRC. METHODS: We used multiplex immunohistochemistry (mIHC) with two panels, each containing five markers, to simultaneously analyze the proportions of immune microenvironment constituents in 59 patients with advanced-stage dMMR CRC and 24 patients with early-stage dMMR CRC. We detected immune cell–associated signatures in the epithelial and stromal regions and evaluated the predictive value of these immune molecules. Student’s t-tests, Mann–Whitney U tests, Cox proportional hazards regression modeling, univariate Cox modeling, and Kaplan–Meier estimation were used to analyze immune cell proportions and survival data. RESULTS: We observed significantly higher proportions of CD8+ cytotoxic T cells (CD8+) (p = 0.001), CD8+ memory T cells (CD8+CD45RO+) (p = 0.032), and CD4+ regulatory T cells (CD4+FOXP3+) (p = 0.011) in the advanced-stage dMMR CRCs than in the early-stage dMMR CRCs. Furthermore, CD3+ T cells with PD-L1 colocalization (CD3+PD-L1+) (p = 0.043) and CD8+ T cells with PD-L1 colocalization (CD8+PD-L1+) (p = 0.005) were consistently more numerous in patients in the advanced stage than those in the early stage. Our analyses revealed that a high proportion of CD3+PD-1+ T cells was an independent prognostic factor of overall survival (OS) [hazard ratios (HR) = 9.6, p < 0.001] and disease-free survival (DFS) (HR = 3.7, p = 0.010) in patients in the advanced stage. CONCLUSION: High numbers of CD8+ cytotoxic T cells and CD8+ memory T cells, which usually represent a cytotoxic function of the adaptive immune system and possibly enhanced inhibition factors, such as CD4+ regulatory T cells and PD-L1 colocalized T cells, were associated with the transformation of the immune microenvironment from the early stage to the advanced stage in dMMR CRCs. Furthermore, CD3+PD-1+ T cells are a prognostic factor for patients with dMMR.
format Online
Article
Text
id pubmed-9163547
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91635472022-06-05 The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry Yan, Hongkai Li, Yaqi Wang, Xiaoyu Qian, Juanjuan Xu, Midie Peng, Junjie Huang, Dan Front Oncol Oncology BACKGROUND: Immune checkpoint inhibitors (ICIs) are quickly becoming key instruments in the treatment of mismatch repair-deficient (dMMR) colorectal cancers (CRCs). Despite their clinical value, ICIs have several limitations associated with their use. Only approximately 15% of all CRCs have a dMMR status, and the overall response rate of ICIs is approximately 40%. The mechanism of ICI resistance is not clear, and its study is limited by the lack of information available on the characterization of the immune microenvironment during the progression from early- to advanced-stage dMMR CRC. METHODS: We used multiplex immunohistochemistry (mIHC) with two panels, each containing five markers, to simultaneously analyze the proportions of immune microenvironment constituents in 59 patients with advanced-stage dMMR CRC and 24 patients with early-stage dMMR CRC. We detected immune cell–associated signatures in the epithelial and stromal regions and evaluated the predictive value of these immune molecules. Student’s t-tests, Mann–Whitney U tests, Cox proportional hazards regression modeling, univariate Cox modeling, and Kaplan–Meier estimation were used to analyze immune cell proportions and survival data. RESULTS: We observed significantly higher proportions of CD8+ cytotoxic T cells (CD8+) (p = 0.001), CD8+ memory T cells (CD8+CD45RO+) (p = 0.032), and CD4+ regulatory T cells (CD4+FOXP3+) (p = 0.011) in the advanced-stage dMMR CRCs than in the early-stage dMMR CRCs. Furthermore, CD3+ T cells with PD-L1 colocalization (CD3+PD-L1+) (p = 0.043) and CD8+ T cells with PD-L1 colocalization (CD8+PD-L1+) (p = 0.005) were consistently more numerous in patients in the advanced stage than those in the early stage. Our analyses revealed that a high proportion of CD3+PD-1+ T cells was an independent prognostic factor of overall survival (OS) [hazard ratios (HR) = 9.6, p < 0.001] and disease-free survival (DFS) (HR = 3.7, p = 0.010) in patients in the advanced stage. CONCLUSION: High numbers of CD8+ cytotoxic T cells and CD8+ memory T cells, which usually represent a cytotoxic function of the adaptive immune system and possibly enhanced inhibition factors, such as CD4+ regulatory T cells and PD-L1 colocalized T cells, were associated with the transformation of the immune microenvironment from the early stage to the advanced stage in dMMR CRCs. Furthermore, CD3+PD-1+ T cells are a prognostic factor for patients with dMMR. Frontiers Media S.A. 2022-05-20 /pmc/articles/PMC9163547/ /pubmed/35669431 http://dx.doi.org/10.3389/fonc.2022.867658 Text en Copyright © 2022 Yan, Li, Wang, Qian, Xu, Peng and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yan, Hongkai
Li, Yaqi
Wang, Xiaoyu
Qian, Juanjuan
Xu, Midie
Peng, Junjie
Huang, Dan
The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
title The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
title_full The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
title_fullStr The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
title_full_unstemmed The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
title_short The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
title_sort alteration of t-cell heterogeneity and pd-l1 colocalization during dmmr colorectal cancer progression defined by multiplex immunohistochemistry
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163547/
https://www.ncbi.nlm.nih.gov/pubmed/35669431
http://dx.doi.org/10.3389/fonc.2022.867658
work_keys_str_mv AT yanhongkai thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT liyaqi thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT wangxiaoyu thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT qianjuanjuan thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT xumidie thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT pengjunjie thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT huangdan thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT yanhongkai alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT liyaqi alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT wangxiaoyu alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT qianjuanjuan alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT xumidie alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT pengjunjie alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry
AT huangdan alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry